Prescription Drug Prices Hit Record Low
On Thursday, the White House announced that prescription drug prices in the U.S. have reached their lowest point in 60 years.
President Donald Trump has consistently emphasized his commitment to lowering these costs. The administration attributed the recent reductions to TrumpRx, a service that delivers certain medications right to patients’ doorsteps. They pointed to the high prices of GLP-1 weight-loss medications, which Trump casually referred to as the “fat drug,” noting that initial doses start at about $150.
The White House stated that thanks to Trump’s ongoing initiatives, prescription drug prices are now significantly decreasing.
“Prescription drug prices PLUMMETING,” the White House posted. “Thanks to President Trump’s promise to SLASH prescription drug costs and TrumpRx, drug prices just saw their sharpest drop in over 60 YEARS. MORE WINNING FOR AMERICA!”
Data from the Bureau of Labor Statistics released Wednesday revealed that prescription drug prices fell by at least 3.1%, marking their steepest annual decline since March 1963. Despite rising overall medical service costs, medicinal drug prices dropped 2.7% over the past year, which is the largest annual drop ever noted.
Interestingly, while inflation continues to be a challenge for U.S. consumers, prescription drug prices have been bucking that trend by declining at a record pace.
“No president in modern history has managed to drastically lower prescription drug prices across the board like President Trump,” stated White House spokesman Kush Desai in an email. “This reflects the President’s readiness to push forward with bold policies that prioritize Americans.”
Another spokesperson expressed, “In just a few months, we implemented these discounts in a way that was meaningful for American patients.”
The Bureau of Labor Statistics assesses pharmacy revenue per prescription by combining patient copays, insurance, and Medicare Part D payouts rather than tracking manufacturer list prices directly.
This means that a decline in the index indicates lower overall consumer and program spending, a trend influenced by increased insurance discounts, government price controls, and a shift towards less expensive medications or direct-pay services like TrumpRx.
